Search Results

Displaying Results 6251-6275 of 12267 "'L'"

Dec 11, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Blue Owl Capital Inc. of Class Action Lawsuit and Upcoming Deadlines - OWL

Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz

More news about: Pomerantz LLP

Dec 11, 2025, 10:00 ET Cision rileva Trajaan, espandendo l'IA e la ricerca intelligente sulle sue piattaforme

PR Newswire – consentono a oltre 75.000 aziende e organizzazioni, tra cui l'84% delle aziende Fortune 500, di vedere ed essere viste, comprendere ed essere comprese dal pubblico che più conta per loro. Contatto con i media Relazioni

More news about: Cision Ltd.

JAECOO 7 SHS eleva el estándar de las SUV súper híbridas al superar a sus competidoras clave en desempeño, autonomía y eficiencia

Dec 11, 2025, 10:00 ET JAECOO 7 SHS eleva el estándar de las SUV súper híbridas al superar a sus competidoras clave en desempeño, autonomía y eficiencia

sistema prioriza la potencia total sobre la linealidad de respuesta. El modelo no solo asegura seguridad y control, también ofrece capacidades como V2L de 3.3 kW, con las que los usuarios pueden alimentar electrodomésticos, dispositivos o equipo especializado durante actividades al aire libre.Gracias

More news about: JAECOO

Dec 11, 2025, 10:00 ET Kessler Topaz Meltzer & Check, LLP Announces Proposed Settlement of the SEB Investment Management AB v. Wells Fargo & Company Securities Action

claims in the Action.A hearing ("Settlement Hearing") will be held on May 5, 2026 at 2:00 p.m. Pacific Time, before the Honorable Trina L. Thompson, United States District Judge for the Northern District of California, either in person in Courtroom 9 – 19th Floor of the Phillip Burton Federal

More news about: Kessler Topaz Meltzer & Check, LLP

Dec 11, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Cepton, Inc. and Certain Officers - CPTN

More news about: Pomerantz LLP

<em>L</em>3 Family Wealth Partners Expands Tax-Smart Retirement Planning Across Midwest & Southeast

Dec 11, 2025, 09:00 ET L3 Family Wealth Partners Expands Tax-Smart Retirement Planning Across Midwest & Southeast

Apple.About L3 Family Wealth PartnersL3 Family Wealth Partners is a family-owned and operated financial planning firm with offices in Minneapolis, MN and Palm Beach

More news about: L3 Family Wealth Partners

Dec 11, 2025, 09:00 ET Avocet Partners Launches with $500 Million Equity Commitment from Oaktree and Lane42

value to investors and exceptional partnership to portfolio companies, driven by a culture of integrity, collaboration, and alignment. Founded by Scott L. Graves, an accomplished investment professional with more than 30 years of public and private credit and equity investing, Lane42 was seeded with a $2

More news about: Avocet Partners

Dec 11, 2025, 08:31 ET The Lupus Research Alliance Announces Inaugural Mechanistic Clinical Award Recipients to Improve Lupus Understanding, Treatment Options

Department of Medical & Molecular Genetics, King's College LondonDr. Cunninghame Graham is studying two immune proteins – OX40 and OX40L – that are associated with genetic risk and disease activity in lupus and are detectable in the blood. Her research explores whether measuring them can

More news about: Lupus Research Alliance

Dec 11, 2025, 08:30 ET CENTURY LITHIUM HIGHLIGHTS RARE EARTH POTENTIAL AT ANGEL ISLAND, NEVADA

rare earth elements and 25% yttrium and heavy rare earth elements. Chloride leaching of the sample yielded solution concentrations of 210 mg/l lithium and 36 mg/l TREO, indicating that the REEs enter solution under the same conditions as used for lithium extraction.Two ion-exchange ("IX") media

More news about: Century Lithium Corp.

Dec 11, 2025, 08:30 ET WERFEN APPLAUDS SIGNIFICANT PUBLICATION URGING ACTION ON THE RISKS OF UNDETECTED HEMOLYSIS

quality improvement. Clin Chem Lab Med. 2009;47(5):616–618. doi:10.1515/CCLM.2009.132Lippi G, Fontana R, Avanzini P, Sandei F, Ippolito L. Influence of spurious hemolysis on blood gas analysis. Clin Chem Lab Med. 2013;51(8):1651–1654. doi:10.1515/cclm-2012-0802O'Hara M, Wheatley

More news about: Werfen

Dec 11, 2025, 08:30 ET Market For Geologic Hydrogen & Carbon Capture Is Burgeoning, With Revenues Projected to Hit Over $50 Billion

Geologic Hydrogen Generation: Active serpentinization within the Bay of Islands Complex produces dissolved hydrogen (H₂) concentrations of 0.06–1.20 mg/L in ultra-basic springs, with highly reducing conditions (Eh as low as -609 mV) and pH values up to 12.3 conducive to ongoing natural hydrogen production.Awaruite

More news about: FN Media Group, LLC

Dec 11, 2025, 08:07 ET Following the US Federal Reserve Meeting, J.S. Held Releases the Lending Climate in America Survey Results

More news about: J.S. Held

Dec 11, 2025, 08:05 ET La Fintech Abu Dhabi de l'ADFW annonce l'avènement d'une nouvelle ère de la finance alimentée par l'innovation et la disruption

principaux, d'autres événements ont eu lieu, tels que le Forum d'Abou Dabi sur l'IA, le Blockchain Abu Dhabi, le Forum sur les risques 4.0, l' événement de Bloomberg sur l'évolution de l'IA : de la théorie à la pratique et le Forum sur les ressources numériques d'Eastpoint. Tout au

More news about: ADGM

Dec 11, 2025, 08:00 ET HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025

attributable to chemotherapy, not HCB1012L GC:58.3% ORR (7/12) for all cohorts evaluated, 77.8% ORR (7/9) for mid-dose cohorts, and 100% DCRTumor shrinkage up to -78.2%1L HER2+ GC: 33% ORR (1/3)1L TNBC: 50% ORR (3/6) and 100% DCRAlvin

More news about: HanchorBio Inc.

Dec 11, 2025, 08:00 ET Stephon Castle Investing in CT Sports Group, the Parent Organization of CT United FC and Connecticut Women's Pro Soccer

post- treatment patient support, and School-by-School in India, which focuses on educating girls and training women to become teachers.Calvin L. Butts Jr. is Co-founder and General Partner of East Chop Capital, a private equity firm with a portfolio spanning real estate, technology, media,

More news about: Connecticut Sports Group

Dec 11, 2025, 07:46 ET Loews Corporation Comments on Delaware Supreme Court's Ruling

NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today that the Delaware Supreme Court issued a ruling in the litigation relating to its 2018 acquisition of the minority limited partner interests

More news about: Loews Corporation

Dec 11, 2025, 07:30 ET TuHURA Biosciences Provides Corporate Update Following Recent Financing

Development Award; Evans MDS Young Investigator Award; American Cancer Society Clinician Scientist Development Grant; Forbeck Scholar Award.Geoffrey L. Uy, MD, Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine,

More news about: TuHURA Biosciences, Inc.

Dec 11, 2025, 07:07 ET Odyssey Functional Energy Expands Across Major U.S. Airports Nationwide with CIBO Express Deal

energy, focus, clarity, mood, and performance, Odyssey is powered by high-potency adaptogens and nootropics, including Organic Lion's Mane, Cordyceps, L-Theanine, Panax Ginseng, and naturally sourced green tea caffeine, with no artificial ingredients and no added sugar. With bold, craveable flavors, Odyssey

More news about: Odyssey Functional Energy

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

Dec 11, 2025, 07:00 ET Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

studied, the median prior lines of therapy for advanced/metastatic disease were two and the majority (87.1%) had prior PD-(L)1 exposure with 16 participants (51.6%) receiving a PD-(L)1 as the most recent treatment prior to receiving study treatment. The maximum tolerated dose was not reached and only one

More news about: Biohaven Ltd.

"I Have More Energy, Sleep Better, and Better Elimination" - Gundry MD Total Restore Earns Rave Reviews for Transforming Gut Health

Dec 11, 2025, 06:00 ET "I Have More Energy, Sleep Better, and Better Elimination" - Gundry MD Total Restore Earns Rave Reviews for Transforming Gut Health

comfort.PepZin GI® (Zinc-L-Carnosine) – A clinically studied compound shown to support the stomach lining, promote digestive comfort, and help maintain the integrity of the digestive tract.✝Gundry MD Total Restore Ingredient BreakdownL-Glutamine: Supports Gut Lining Integrity

More news about: Gundry MD

Dec 11, 2025, 06:00 ET IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM). IDEAYA expects to report median progression-free survival (PFS) data from this trial in the first

More news about: IDEAYA Biosciences, Inc.

LEPAS <em>L</em>8 Exquisite Space: Suaka Emosional yang Penuh Ketenangan untuk Gaya Hidup Sehari-hari

Dec 11, 2025, 02:05 ET LEPAS L8 Exquisite Space: Suaka Emosional yang Penuh Ketenangan untuk Gaya Hidup Sehari-hari

Gaya hidup elegan berawal dari hal-hal kecil yang membawa kebahagiaan. Di dalam Exquisite Space LEPAS L8, pengguna memasuki sebuah suaka emosional yang membawa ketenangan. Jok depan LEPAS L8, dapat direbahkan sepenuhnya, sedangkan proyektor dan sistem hiburan mobil menciptakan suasana bioskop pribadi.

More news about: LEPAS

Dec 11, 2025, 00:50 ET 新橋生物公佈 Ragistomig 1期劑量拓展研究數據：療效可比，安全性顯著提升

Ragistomig 是一種 4-1BB X PD-L1 雙特異性抗體，旨在治療使用檢查點抑制劑後復發或難治的晚期或轉移性實體瘤患者。作為癌症治療的支柱，檢查點抑制劑市場規模達數十億美元，但廣泛存在的耐藥性限制了其療效。研究目標已達成：對於既往使用過抗PD-(L)1等免疫療法後難治或復發的患者，新的每6週一次（Q6W） 延長給藥間隔方案不僅展現出了令人鼓舞的抗腫瘤療效和免疫學數據，相較於此前每2週一次（Q2W）的方案，安全性也顯著改善。本次發佈的海報展示了包含CD8+ 細胞增殖和記憶 T 細胞活化在內的積極免疫學數據。

More news about: 新橋生物

Изысканное пространство LEPAS <em>L8:</em> умиротворяющее эмоциональное убежище для эмоционального стиля жизни

Dec 10, 2025, 22:22 ET Изысканное пространство LEPAS L8: умиротворяющее эмоциональное убежище для эмоционального стиля жизни

расслабление, эмоциональное равновесие и пространство, истинно принадлежащее только им. Компания LEPAS делает изысканное пространство модели LEPAS L8 мобильным эмоциональным убежищем, превращая каждую поездку и паузу в моменты элегантной жизни и непринужденного комфорта.